MTOR and lymphatic malformation: Similarly, the mTOR inhibitor, sirolimus, has been shown to limit downstream VEGFR3 signaling thereby aiding in diseases where lymphatic malformations occur (Baluk et al., 2017; Ozeki and Fukao, 2019; Ozeki et al., 2019a,b,c).